News

Laurent Pharmaceuticals Provides Clinical Development Update

8 April 2021

Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 PatientsCompletes...

Read More

Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial in the United States

27 August 2020

The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against...

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022